Fragment 176-191 Research Overview
Fragment 176-191 is a synthetic peptide comprising amino acids 176-191 from the C-terminal region of human growth hormone. This 16-amino acid sequence represents the specific region responsible for the lipolytic properties of growth hormone without the growth-promoting effects. Researchers at Stroid UK Shop investigate this peptide fragment for its selective metabolic modulation properties in controlled laboratory environments. The peptide maintains the fat-oxidation characteristics of the parent hormone while eliminating other biological activities, making it valuable for targeted metabolic research studies.
Laboratory Research Applications
Research scientists examine Fragment 176-191 in various metabolic pathway studies, particularly focusing on adipocyte metabolism and energy expenditure mechanisms. The peptide’s selective action on lipolytic pathways allows researchers to study fat oxidation processes independently of growth hormone’s other effects. Laboratory investigations include cellular metabolism assays, adipose tissue culture studies, and metabolic rate measurements in research models. Scientists studying peptide mechanisms often compare Fragment 176-191’s effects with other metabolic modulators to understand selective pathway activation. The compound’s stability and specific activity profile make it suitable for extended research protocols examining metabolic regulation at the cellular level.
Technical Specifications
| Peptide Sequence | YLRIVQCRSVEGSCGF |
|---|---|
| Molecular Weight | 1815.08 g/mol |
| CAS Number | Verify with supplier |
| Purity | ≥98% HPLC |
| Storage | -20°C lyophilised, 2-8°C reconstituted |
| Solubility | Water, bacteriostatic water |
| Appearance | White lyophilised powder |
Researchers investigating metabolic pathways often examine this fragment alongside compounds available in our selective androgen receptor modulator collection for comparative studies. The peptide’s selective mechanism provides researchers with a valuable tool for isolating specific metabolic effects in their experimental protocols.
Research Compliance Statement
Fragment 176-191 is supplied exclusively for in-vitro research purposes and laboratory investigations. This compound is not intended for human consumption, clinical applications, or therapeutic use. Researchers must ensure compliance with all applicable laboratory safety protocols and institutional guidelines when handling this research compound. Studies involving peptide fragments require appropriate laboratory facilities and qualified personnel experienced in peptide research methodologies.
